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Risk factors for severe systemic sting 
reactions in wasp (Vespula spp.) and honeybee 
(Apis mellifera) venom allergic patients
Danielle Fehr1, Sara Micaletto1, Thomas Moehr2 and Peter Schmid‑Grendelmeier1* 
Abstract 
Background: Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. 
This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and honeybee 
(Apis mellifera) venom allergic patients and analyses the correlation between diagnostic test results and the severity of 
the allergic reaction.
Methods: 480 patients suffering from wasp or honeybee venom allergy were included in this retrospective case 
series. Only individuals allergic to Vespula spp. but not to other vespids such as Polistes were considered. The sever‑
ity of their systemic field sting reaction was analysed with regard to the amount of specific IgE antibodies to whole 
venom extracts and to major allergens of honeybee and/or wasp venom. Furthermore, the following potential risk 
factors for severe sting reactions were examined: age, sex, latency time, skin symptoms, baseline serum tryptase levels 
and the concentration of venom inducing a positive intracutaneous test.
Results: The two following indicators for severe systemic sting reactions in honeybee and wasp venom allergic 
patients have been identified: a short latency time and the absence of skin symptoms. The patient’s age and baseline 
serum tryptase levels have been found to positively correlate with the grade of the sting reaction only in individuals 
allergic to wasp venom. No correlation could be found between the degree of sensitisation and the severity of the 
allergic reaction. Neither the amount of specific IgE antibodies to whole venom extracts nor to major allergens were 
significantly associated with the severity of the sting reaction.
Conclusion: The clinical history is essential for the allergological workup and therapeutic decision on Hymenoptera 
venom allergies. A short latency time and the absence of skin symptoms are indicators for severe systemic sting reac‑
tions, followed by the patient’s age and baseline serum tryptase levels.
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Background
Hymenoptera stings are among the most common rea-
sons for anaphylaxis [1, 2]. In Europe, between 0.3 
and 7.5% of the general population are affected by sys-
temic anaphylactic sting reactions [3]. Different clini-
cal manifestations are possible, ranging from a mere 
skin reaction (flush, pruritus, urticaria, angioedema) to 
gastro-intestinal or respiratory symptoms, cardiovascular 
involvement or in some cases even death [4].
Different studies have investigated risk factors for 
severe sting reactions. Among others, the following 
aspects are mentioned in literature: male sex, older age, 
a large number of stings, a short time interval between 
stings, the localisation of the sting, the absence of skin 
symptoms, high baseline serum tryptase (BST) levels as 
well as cardiovascular comorbidity and medication [3, 5–
11]. However, little research has been conducted to eval-
uate potential differences between wasp (Vespula spp.) 
and honeybee (Apis mellifera) venom allergic patients.
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The diagnostic workup of patients with suspected 
Hymenoptera venom allergy includes a comprehensive 
clinical history, skin tests and the measurement of spe-
cific IgE antibodies (sIgE) to whole venom preparations. 
Additional in vitro tests can be necessary in case of unex-
pected negative results. BST levels are evaluated in case 
of systemic anaphylaxis [12, 13]. In recent years, diagnos-
tic accuracy of insect sting allergies has been improved 
by using molecular diagnostics. SIgE to major allergens 
such as phospholipase A2 (rApi m 1) in honeybee venom 
or phospholipase A1 (rVes v 1) and antigen 5 (rVes v 5) in 
wasp venom can help to distinguish genuine double sen-
sitisation from cross-reactivity [13–15].
We undertook a consecutive retrospective case series 
to investigate the correlation between the amount of sIgE 
to whole venom extracts respectively to major allergens 
and the severity of the systemic sting reaction (SSR). An 
additional aim of this study was to evaluate the follow-
ing potential risk factors for severe SSR in both wasp 
and honeybee venom allergic patients: age, sex, latency 
time, skin symptoms, BST levels and the concentration of 
venom inducing a positive intracutaneous test.
Methods
Patients
This consecutive retrospective case series included 480 
patients suffering from Vespula spp. (hereafter referred 
to as wasp) or Apis mellifera (hereafter referred to as 
honeybee) venom allergy. Patients allergic to other 
vespids such as Polistes, Vespa crabro or Dolichovespula 
were not included. From January 2010 to December 
2016, the respective individuals were referred to the 
Department of Dermatology of the University Hospital 
Zurich in view of a venom immunotherapy (VIT). As a 
consequence, all patients met the criteria of the European 
Academy of Allergy and Immunology for the initiation of 
VIT. VIT is indicated in sensitised individuals who suf-
fered a SSR exceeding generalised cutaneous symptoms. 
It is also recommended if it improves quality of life in 
adult patients with only generalised skin reactions [16]. 
Individuals were included only if the SSR occurred fol-
lowing a Hymenoptera field sting. Patients sensitised to 
both wasp and honeybee venom were excluded. In addi-
tion, only laboratory values measured prior to the initia-
tion of VIT were taken into account.
In patients with elevated BST levels (n = 35) a detailed 
clinical history and careful inspection of the skin was 
performed to detect any signs of underlying mastocy-
tosis. If BST was > 20  μg/l (n  =  14), an osteodensitom-
etry was initiated to detect an associated osteoporosis; 
if symptoms highly suspicious for systemic mastocyto-
sis were reported or BST was > 30  μg/l, a bone marrow 
aspiration was performed (n =  10). Detection of c-KIT 
mutation (D816V) in peripheral blood would have been 
another useful diagnostic test in this patients but was not 
available at the time of the data collection.
Classification of sting reactions
The systemic reactions to Hymenoptera stings were clas-
sified according to H. L. Mueller [17] on a scale from I 
to IV (Table  1). Details about the allergic episode were 
obtained from medical reports and letters of referral.
Intracutaneous skin tests
Intracutaneous tests were performed with 0.02 ml doses 
of wasp and honeybee venom extracts (Pharmalgen 
ALK-Abelló aqueous extracts, Hørsholm, Denmark). 
Beginning with a concentration of 0.00001  µg/ml, the 
injected concentration was increased by a factor of 10 
every 15 min. If a wheal with a diameter of 3 mm or more 
occurred within those 15  min, the test was considered 
positive and no further application was made. If no reac-
tion occurred until the concentration of 1 µg/ml, the test 
was stopped and considered negative. NaCl 0.9% served 
as negative and histamine as positive control. Skin test 
results obtained by a referring physician were not taken 
into account for statistical analyses.
Laboratory
BST as well as sIgE levels (honeybee i1, rApi m 1, wasp 
i3, rVes v 1, rVes v 5) were measured with the Immu-
noCAP-System™ (Thermo Fisher Scientific, Waltham, 
USA). The tests were performed according to the 
manufacturer’s instructions. Only laboratory values 
Table 1 Classification of systemic sting reactions (after H. L. Mueller [16], modified by U. R. Mueller [4])
Grade Symptoms
I Generalised urticaria, itching, malaise, anxiety
II Any of the above plus two or more of the following: angioedema (grade II also if alone), constriction in chest, nausea, vomiting, diarrhoea, 
abdominal pain, dizziness
III Any of the above plus two or more of the following: dyspnoea, wheezing, stridor (any of these alone are grade III), dysphagia, dysarthria, 
hoarseness, weakness, confusion, feeling of impending disaster
IV Any of the above plus two or more of the following: fall in blood pressure, collapse, loss of consciousness, incontinence (urine, stool), cyanosis
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determined before the beginning of VIT were included 
in the dataset. Values established by referring hospi-
tals were not considered in statistical analyses due to 
potential variations in measurements.
Statistics
STATA Version 13.0 was used for statistical analyses. 
A p-value of less than 0.05 was considered as being 
statistically significant. The main outcome variable 
was the grade of SSR. Since it is ordinally defined on 
a scale from one to four, ordinal logistic regressions 
were used. The grade was separately regressed on 
each potential risk factor, always controlling for the 
patient’s age and sex. The underlying proportional 
odds assumption was tested by Brant’s Wald test [18]. 
The assumption was rejected two times: in the regres-
sion on age for honeybee venom allergic patients and 
on BST for wasp venom allergic patients. However, the 
insignificance of the former and the significance of the 
latter were confirmed by the Jonckheere-Terpstra test. 
Regarding BST levels, a multivariate logistic regression 
on a grade IV dummy variable could additionally con-
firm the positive correlation.
For analyses with a nominally scaled outcome vari-
able (BST level or concentration of sIgE) Spearman’s 
non-parametric rank correlation tests were conducted. 
Regarding the presence of an elevated BST level, 
patients were compared by a Chi square contingency 
table.
Results
Patient characteristics
A total of 480 patients were included in this study. Con-
sisting of 243 males (50.6%) and 237 females (49.4%), 
the data were almost equally balanced in terms of sex. 
Patients were between 6 and 76 years old, the average age 
being 41.6  years. 180 patients (37.5%) suffered a grade 
IV sting reaction, 256 reactions (53.3%) were classified 
as grade III, 33 reactions (6.9%) as grade II and only 10 
patients (2.1%) had a grade I sting reaction. In one case, 
the information about the allergic reaction was contra-
dictory and therefore, the grade could not be determined. 
The frequency of the grades according to each insect is 
shown in Fig. 1. In 330 patients (68.8%), the culprit insect 
was a wasp (Vespula spp.) and in 150 patients (31.3%) a 
honeybee (Apis mellifera). On average, it took 13 min to 
the onset of symptoms. 90% of the reactions occurred 
within 30  min after the sting. Cutaneous manifesta-
tions were present in 326 patients (67.9%), 99 individu-
als (20.6%) did not show any skin symptoms and for the 
remaining ones, the information was missing. BST levels 
were measured in 437 patients of whom 35 (8.0%) had an 
elevated BST level (defined as ≥ 11.4  µg/l). An overview 
of the patient characteristics is given in Table 2.
Risk factors for a severe sting reaction
Whether the patient was stung by a honeybee or a wasp 
did not directly influence the severity of SSR (control-
ling for age and sex, p = 0.36). However, the culprit 
insect had an indirect effect by changing the signifi-
cance of potential risk factors. Therefore, the same 
statistical analyses have been carried out for both 
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Hymenoptera separately. The p-values of the ordinal 
logistic regressions are summarised in Table 3.
Wasp venom allergic patients
Only patients suffering from an allergy to Vespula spp. 
were included in this study, while individuals allergic to 
other vespids such as Polistes, Vespa crabro or Dolicho-
vespula were not taken into account. The patient’s age 
positively correlated with the severity of SSR (p < 0.01). 
Thus, the older the patient is, the more severe the aller-
gic reaction tends to be (Fig.  2a). Furthermore, a sta-
tistically significant positive correlation between the 
individual’s age and the measured BST level has been 
identified (p < 0.01). In contrast, the patient’s sex did 
not have any influence on the degree of clinical reactiv-
ity (p = 0.16).
Another indicator for severe SSR was a short latency 
time (Fig. 2b). On average, the faster the allergic reac-
tion occurred after the sting, the more severe it was 
(p = 0.04).
Along with older age and a short latency time, the 
absence of skin symptoms has been found to be a risk 
factor for severe sting reactions. There was a signifi-
cant positive correlation between the nonappearance of 
cutaneous symptoms (such as flush, pruritus, urticaria 
or angioedema) and the severity of reaction (p < 0.01). 
In addition, the absence of skin manifestations was 
associated with high BST levels (p = 0.01).
BST levels were determined in 307 patients suffer-
ing from an allergy to wasp venom. Analyses showed a 
statistically significant positive correlation between the 
degree of severity and the BST level (p = 0.045).
There was no significant association between the 
amount of sIgE to wasp venom (i3) and the severity of 
SSR (p = 0.25). Likewise, no correlation between sIgE to 
major allergens (rVes v 1, rVes v 5) and the grade could 
be found (p = 0.72 and p = 0.26).
Table 2 Patient characteristics (percentage or  standard 
deviation in parentheses)
Number 
of patients
Total Wasp venom 
allergy
Honeybee 
venom 
allergy
480 330 150
Sex
 Female 237 (49.4%) 163 (49.4%) 74 (49.3%)
 Male 243 (50.6%) 167 (50.6%) 76 (50.7%)
Age (years)
 Mean 41.6 42.5 39.3
 Range 6–76 6–76 9–69
Severity of the allergic reaction
 Grade I 10 (2.1%) 4 (1.2%) 6 (4.0%)
 Grade II 33 (6.9%) 23 (7.0%) 10 (6.7%)
 Grade III 256 (53.3%) 171 (51.8%) 85 (56.7%)
 Grade IV 180 (37.5%) 131 (39.7%) 49 (32.7%)
Latency time (min)
 Mean 13.0 (± 14.9) 12.4 (± 13.5) 14.7 (± 17.9)
Cutaneous symptoms
 Yes 326 (67.9%) 224 (67.9%) 102 (68.0%)
 No 99 (20.6%) 70 (21.2%) 29 (19.3%)
 Missing 55 (11.5%) 36 (10.9%) 19 (12.7%)
Mean sIgE (kU/l)
 To honeybee 
venom (i1)
6.07 (± 15.5) 1.45 (± 5.5) 17.31 (± 23.9)
 To rApi m 1 2.30 (± 10.2) 0.11 (± 0.3) 7.86 (± 18.1)
 To wasp venom (i3) 9.13 (± 21.4) 12.28 (± 24.6) 1.34 (± 2.8)
 To rVes v 1 5.71 (± 21.0) 7.59 (± 24.2) 0.42 (± 1.3)
 To rVes v 5 7.34 (± 18.1) 9.80 (± 20.7) 0.77 (± 2.8)
BST level
 Measured 437 307 130
 Normal 
(< 11.4 µg/l)
402 (92.0%) 277 (90.2%) 125 (96.2%)
 Elevated 
(≥ 11.4 µg/l)
35 (8.0%) 30 (9.8%) 5 (3.8%)
Intracutaneous test
 Performed 428 300 128
 0.00001 µg/ml 66 (15.4%) 40 (13.3%) 26 (20.3%)
 0.0001 µg/ml 3 (0.7%) 3 (1.0%) 0 (0.0%)
 0.001 µg/ml 69 (16.1%) 52 (17.3%) 17 (13.3%)
 0.01 µg/ml 150 (35.0%) 111 (37.0%) 39 (30.5%)
 0.1 µg/ml 98 (22.9%) 70 (23.3%) 28 (21.9%)
 1 µg/ml 35 (8.2%) 22 (7.3%) 13 (10.2%)
 Negative 7 (1.6%) 2 (0.7%) 5 (3.9%)
Table 3 P-values of  the  ordinal logistic regressions 
controlling for age and sex
* p < 0.05
Variables Wasp
Grade
Honeybee
Grade
Age < 0.01* 0.48
Male 0.16 0.34
Latency time 0.04* 0.02*
Cutaneous symptoms < 0.01* 0.02*
i3 0.25 0.63
rVes v 1 0.72 0.41
rVes v 5 0.26 0.09
i1 0.32 0.76
rApi m 1 0.96 0.46
BST level 0.045* 0.15
Intracutaneous test 0.73 0.58
Page 5 of 8Fehr et al. Clin Transl Allergy            (2019) 9:54 
Intracutaneous tests were undertaken on 300 patients 
allergic to wasp venom. Analyses could not identify a 
statistically significant relationship between the venom 
concentration required for a positive test result and 
the severity of SSR (p = 0.73). Yet, a strong correlation 
between the intracutaneous test result and the amount of 
sIgE to wasp venom was detected (p < 0.01).
Honeybee venom allergic patients
When it comes to the patient’s age, there is a difference 
between patients suffering from an allergy to honeybee 
venom compared to those allergic to wasp venom. Con-
cerning honeybees, there was no statistically significant 
correlation between the individual’s age and the grade 
of SSR (p = 0.48, Fig. 2c). The patient’s sex was again not 
associated with the severity of SSR (p = 0.34).
It was possible to identify the two following risk factors 
for severe SSR in individuals allergic to honeybee venom: 
a short latency time and the absence of skin symptoms. 
Generally, the sting reaction was more severe if the 
time until the onset of symptoms was shorter (p = 0.02, 
Fig.  2d). Skin symptoms were inversely related to the 
degree of severity as well (p = 0.02). Hence, if no cuta-
neous manifestations occurred, the average grade was 
higher. In contrast to wasp venom allergic patients, there 
was no statistically significant correlation between the 
presence of skin symptoms and the measured BST level 
(p = 0.46).
Five honeybee venom allergic individuals out of 130 had 
an elevated BST level (3.8%). In contrast to the patients 
allergic to wasp venom, the concentration of BST did not 
significantly correlate with the grade (p = 0.15). Notwith-
standing, the BST level has been found to increase with 
age (p < 0.01).
The concentration of sIgE to the whole venom prepa-
ration (i1) and to the major allergen (rApi m 1) did not 
significantly correlate with the grade of SSR (p = 0.76 and 
p = 0.46).
As was the case for wasp venom allergic patients, the 
result of the intracutaneous test was not significantly 
associated with the severity of SSR (p = 0.58). Neverthe-
less, statistical analyses showed a strong relation between 
Fig. 2 a Association between age and grade for wasp venom allergic patients. b Association between latency time and grade for wasp venom 
allergic patients. c Association between age and grade for honeybee venom allergic patients. d Association between latency time and grade for 
honeybee venom allergic patients
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the test result and the amount of sIgE to honeybee venom 
(p < 0.01).
Discussion
The present study was designed to investigate the sig-
nificance of different laboratory values and potential 
risk factors to predict the severity of a SSR following a 
Hymenoptera field sting. Our findings support the asser-
tion that the degree of sensitisation does not correlate 
with the severity of the sting reaction [3, 19–27]. Neither 
the concentration of venom inducing a positive intra-
cutaneous test, nor the amount of sIgE to whole venom 
preparations or to venom components were significantly 
associated with the grade of SSR. Given the fact that 
asymptomatic sensitisation is present in up to 40.7% of 
the population [19, 28], this is not unexpected. However, 
there was a statistically significant positive correlation 
between the skin test reactivity and the level of venom-
specific IgE.
We found the following risk factors for severe SSR in 
wasp venom allergic patients: a short latency time, the 
absence of skin symptoms, older age and high BST levels. 
Interestingly, our results varied depending on the culprit 
insect. For patients allergic to honeybee venom, only the 
absence of cutaneous symptoms and a short latency time 
could be established as risk factors.
Latency time
Usually, a shorter time interval between the sting and 
the beginning of symptoms indicates a more severe 
SSR. Similar to this finding, Stoevesandt et  al. [9] ret-
rospectively identified a latency time of less than 5  min 
as an indicator for severe SSR. In a prospective study 
evaluating risk factors by means of a sting challenge, the 
latency time also correlated negatively with the severity 
of reaction [20]. In our study, 75% of the grade IV reac-
tions occurred during the first 10 min after the sting, the 
median time interval being 5 min. This is consistent with 
Sturm et al. [29] who observed that cardiovascular symp-
toms usually appear within 10 min.
Cutaneous symptoms
The absence of skin symptoms (flush, pruritus, urticaria, 
angioedema) is significantly associated with severe SSR. 
This statement could be established for both wasp and 
honeybee venom allergic patients and is in line with pre-
vious findings [9]. In literature, the nonappearance of 
cutaneous manifestations has been described as a typical 
observation in patients suffering from severe cardiovas-
cular symptoms after a Hymenoptera sting [29]. Con-
cerning patients allergic to wasp venom, we could even 
observe a statistically significant association between the 
lack of skin involvement and high BST levels. Previous 
studies suggested that measurement of BST levels and 
medical clarification of possible clonal mast cell disorders 
are of great importance in patients with severe SSR who 
did not report any skin symptoms [9, 14, 30, 31]. We sup-
port this recommendation especially in regard to wasp 
venom allergic patients.
There are two possible explanations for the absence of 
skin symptoms in severe SSR. First, there could be a recall 
bias. Patients focus on the most threatening symptom 
such as loss of consciousness and do not remember the 
less severe symptoms. However, witnesses of the SSR or 
medical staff often confirm the lack of cutaneous involve-
ment [9, 25]. Second, epinephrine is set free to counter-
act in patients suffering from circulatory symptoms. This 
hormone induces a peripheral vasoconstriction and thus 
conceivably inhibits the development of skin symptoms 
[9, 29, 30].
Age
Concerning patients allergic to wasp venom, there was 
a statistically significant correlation between the age 
and the severity of SSR. Several studies have already 
described this age-related increase in severity [5, 8, 9, 
20, 24, 32–34]. A potential reason for the greater risk of 
severe SSR (or even death [3, 10]) with increasing age is 
an impaired cardiovascular and/or pulmonary function 
due to pre-existing diseases [5, 9, 35]. Not only does this 
lead to a reduced potential to compensate and recover 
but also to the intake of medication such as ACE inhibi-
tors or beta-blockers, which in turn are discussed as 
risk factors for severe allergic reactions [34, 36]. As rec-
ommended by the European Academy of Allergy and 
Immunology, physicians should consider a long-term or 
lifelong VIT in older patients [37]. Surprisingly, no sta-
tistically significant association between the patient’s age 
and the grade of SSR could be found for honeybee venom 
allergic individuals. There is a need for further research 
to elaborate on the reasons behind this finding.
BST levels
Our analyses revealed that in patients allergic to wasp 
venom, higher BST levels were significantly associated 
with more severe SSR. The relation between BST lev-
els and degree of severity has already been investigated 
in multiple other studies. Most of them did find a sta-
tistically significant positive association [5, 8, 9, 24, 34], 
whereas Sturm et al. [29] did not observe an influence of 
BST levels on the severity of the sting reaction. The find-
ing that BST levels rise with increasing age is more con-
troversial and needs further clarification. While Haeberli 
et  al. [24] and Stoevesandt et  al. [9] did not detect any 
association, Kucharewicz et  al. [32], Blum et  al. [5] and 
Guenova et al. [8] found a statistically significant one.
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The fact that the correlation between BST levels and 
the severity of SSR did not reach statistical significance in 
honeybee venom allergic patients potentially stems from 
the smaller number of observations (n = 130 for honey-
bees, n = 307 for wasps). It is, however, interesting that 
among the individuals allergic to honeybee venom, only 
five out of 130 (3.8%) had an elevated BST level, whereas 
the number was significantly higher in wasp venom aller-
gic patients (30 out of 307, 9.8%). Hence, 85.7% of the 
patients with increased BST levels were allergic to wasp 
venom. In the study of Haeberli et  al., this percentage 
was similar (75%). They hypothesised that wasp venom 
contained peptides which are stronger activators of mast 
cells than those in honeybee venom. Thus, wasp venom 
could intensify the IgE mediated response more easily. As 
a consequence, mastocytosis would be more relevant in 
aggravating the sting reaction in wasp than in honeybee 
venom allergic patients [24]. However, further research is 
needed to examine this theory.
Limitations
The first limitation of our research results from the retro-
spective design of the study. This implicates that we had 
to rely on the patient’s memory and accept a potential 
recall bias. However, we preferred the evaluation of past 
field stings because of the danger of provoking serious 
reactions inherent in sting challenges. The second limita-
tion is that the time interval between the sting and the 
diagnostic workup varied, as the patients did not always 
search medical aid immediately.
Conclusions
The degree of sensitisation does not indicate the severity 
of a previous sting reaction. Therefore, a comprehensive 
clinical history with focus on indicators for severe sting 
reactions is indispensable. The absence of skin symptoms 
and a short latency time are associated with severe SSR 
in both wasp and honeybee venom allergic patients. The 
patient’s age and BST levels significantly correlate with 
the grade in patients allergic to wasp venom only.
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